New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
11:29 EDTCTRX, CVS, ESRXCatamaran plunges after full year profit outlook trails expectations
Shares of Catamaran (CTRX), a provider of pharmacy benefit management services, are sinking after the company's fiscal 2014 profit outlook significantly trailed expectations. WHAT'S NEW: This morning, Catamaran reported fourth quarter earnings per share of 56c and revenue of $4.53B, topping expectations of 54c and $4.04B, respectively. The company forecast FY14 adjusted EPS of $2.04-$2.19, compared to consensus of $2.41. FY14 revenue was guided to $20B-$21B, versus consensus of $20.16B. ANALYST REACTION: This morning, analyst commentary was positive. Research firm Jefferies said weakness in the shares of Catamaran was a buying opportunity. The firm recommended buying the stock on weakness saying Catamaran is likely to sustain its strong top-line growth. Jefferies had a Buy rating on the stock with a $70 price target. Another firm, Leerink, said Catamaran's long-term growth drivers remained intact despite its weaker than expected 2014 outlook. It kept an Outperform rating on the stock. PRICE ACTION: In late morning trading, Catamaran fell $6.03, or about 11.6%, to $45.78 on nearly four times its average daily trading volume. Including today's slide, the stock has lost about 17% over the past twelve months. OTHERS TO WATCH: Other firms that provide pharmacy benefit management services include Express Scripts (ESRX) and CVS Caremark (CVS).
News For CTRX;ESRX;CVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
07:36 EDTESRXExpress Scripts price target raised to $90 from $85 at Leerink
Subscribe for More Information
06:25 EDTCTRXCatamaran to acquire Healthcare Solutions for $405M
Subscribe for More Information
06:05 EDTCTRXCatamaran sees FY15 adjusted EPS $2.45-$2.60, consensus $2.59
Subscribe for More Information
06:04 EDTCTRXCatamaran reports Q4 adjusted EPS 67c, consensus 61c
Subscribe for More Information
February 25, 2015
15:05 EDTCTRXNotable companies reporting before tomorrow's open
Subscribe for More Information
10:11 EDTESRXExpress Scripts says willing to do 'tranformational' deal
Subscribe for More Information
February 24, 2015
13:23 EDTCTRX, CVS, ESRXLeerink healthcare technology analyst holds analyst/industry conference call
Healthcare Tech & Distribution Analyst Larsen discusses th 2016 Pharmacy Benefits Management (PBM) selling season, the impact of the Hep C PBM formulary negotiations on the selling season and specialty drug trend and areas of opportunity for PBMs on an Analyst/Industry conference call to be held on March 5 at 2 pm.
08:05 EDTCTRXCatamaran price target raised to $61, risk/reward attractive, says Credit Suisse
Subscribe for More Information
February 23, 2015
18:02 EDTESRXOn The Fly: After Hours Movers
Subscribe for More Information
16:04 EDTESRXExpress Scripts sees Q1 EPS $1.07-$1.11, consensus $1.16
Subscribe for More Information
16:03 EDTESRXExpress Scripts sees FY15 EPS $5.35-$5.49, consensus $5.44
Subscribe for More Information
16:02 EDTESRXExpress Scripts reports Q4 EPS 1.39, consensus $1.38
Subscribe for More Information
15:23 EDTESRXNotable companies reporting after market close
Subscribe for More Information
06:28 EDTESRXExpress Scripts weekly volatility elevated into Q4 and outlook
Subscribe for More Information
February 18, 2015
05:36 EDTESRXExpress Scripts to host investor meeting
Investor meeting to be held in St. Louis on February 25 at 8:30 am. Webcast Link
February 17, 2015
17:29 EDTESRXBerkshire Hathaway gives quarterly update on stakes, exits Exxon Mobil
Subscribe for More Information
10:01 EDTCVSCVS says PCSK9 inhibitors could cost system $150B annually
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use